FY2017 EPS Estimates for CytoSorbents Corp. Decreased by Zacks Investment Research (CTSO)
CytoSorbents Corp. (NASDAQ:CTSO) – Zacks Investment Research cut their FY2017 earnings per share estimates for CytoSorbents Corp. in a research note issued to investors on Monday. Zacks Investment Research analyst B. Marckx now anticipates that the firm will post earnings per share of ($0.35) for the year, down from their prior forecast of ($0.31). Zacks Investment Research also issued estimates for CytoSorbents Corp.’s FY2018 earnings at ($0.21) EPS.
CTSO has been the topic of a number of other research reports. B. Riley began coverage on shares of CytoSorbents Corp. in a report on Thursday, October 6th. They set a “buy” rating and a $11.25 target price on the stock. Maxim Group restated a “buy” rating and set a $8.00 target price on shares of CytoSorbents Corp. in a report on Wednesday, October 5th. Brean Capital began coverage on shares of CytoSorbents Corp. in a report on Tuesday, October 4th. They set a “buy” rating and a $24.00 target price on the stock. HC Wainwright restated a “buy” rating on shares of CytoSorbents Corp. in a report on Tuesday, November 8th. Finally, Aegis began coverage on shares of CytoSorbents Corp. in a report on Wednesday, October 26th. They set a “buy” rating and a $20.00 target price on the stock. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $15.05.
Shares of CytoSorbents Corp. (NASDAQ:CTSO) traded up 3.77% during trading on Wednesday, reaching $5.50. 32,377 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $5.76 and a 200 day moving average price of $5.06. The firm’s market cap is $139.90 million. CytoSorbents Corp. has a 12 month low of $3.11 and a 12 month high of $7.48.
A number of institutional investors have recently modified their holdings of CTSO. Citadel Advisors LLC acquired a new position in shares of CytoSorbents Corp. during the third quarter worth $106,000. Advisor Group Inc. raised its position in shares of CytoSorbents Corp. by 1.1% in the third quarter. Advisor Group Inc. now owns 305,145 shares of the company’s stock worth $1,953,000 after buying an additional 3,300 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of CytoSorbents Corp. by 13.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 29,955 shares of the company’s stock worth $192,000 after buying an additional 3,495 shares during the period. 6.82% of the stock is owned by institutional investors and hedge funds.
About CytoSorbents Corp.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Stock Ratings for CytoSorbents Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoSorbents Corp. and related stocks with our FREE daily email newsletter.